Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Mallinckrodt
Citi
US Army
Julphar
McKesson
Colorcon
Chinese Patent Office
Express Scripts
Teva
Farmers Insurance

Generated: August 20, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 050797

« Back to Dashboard
NDA 050797 describes ZMAX, which is a drug marketed by Pf Prism Cv and is included in one NDA. It is available from two suppliers. There are four patents protecting this drug. Additional details are available on the ZMAX profile page.

The generic ingredient in ZMAX is azithromycin. There are thirty-one drug master file entries for this compound. Fifty-six suppliers are listed for this compound. Additional details are available on the azithromycin profile page.

Summary for NDA: 050797

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:4
Therapeutic Class:Antibacterials
Formulation / Manufacturing:see details

Pharmacology for NDA: 050797

Ingredient-typeMacrolides

Suppliers and Packaging for NDA: 050797

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ZMAX
azithromycin
FOR SUSPENSION, EXTENDED RELEASE;ORAL 050797 NDA Pfizer Laboratories Div Pfizer Inc 0069-4170 0069-4170-34 1 BOTTLE in 1 CARTON (0069-4170-34) > 60 mL in 1 BOTTLE
ZMAX
azithromycin
FOR SUSPENSION, EXTENDED RELEASE;ORAL 050797 NDA Rebel Distributors Corp 21695-444 21695-444-60 60 mL in 1 BOTTLE (21695-444-60)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:FOR SUSPENSION, EXTENDED RELEASE;ORALStrengthEQ 2GM BASE/BOT
Approval Date:Jun 10, 2005TE:RLD:Yes
Patent:► SubscribePatent Expiration:May 30, 2017Product Flag?YSubstance Flag?Delist Request?
Patent:► SubscribePatent Expiration:Jul 31, 2018Product Flag?Substance Flag?YDelist Request?
Patent:► SubscribePatent Expiration:Feb 14, 2024Product Flag?YSubstance Flag?Delist Request?

Expired Orange Book Patents for NDA: 050797

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pf Prism Cv
ZMAX
azithromycin
FOR SUSPENSION, EXTENDED RELEASE;ORAL050797-001Jun 10, 2005► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Cantor Fitzgerald
Cipla
Citi
Argus Health
McKinsey
Novartis
Colorcon
Boehringer Ingelheim
Cerilliant
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot